| 39.34 -1.57 (-3.84%) | 01-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 54.38  |
1-year : | 60.02 |
| Resists | First : | 46.56 |
Second : | 51.38 |
| Pivot price | 45.91 |
|||
| Supports | First : | 38.75 |
Second : | 32.24 |
| MAs | MA(5) : | 44.01 |
MA(20) : | 46.01 |
| MA(100) : | 50.71 |
MA(250) : | 48.45  |
|
| MACD | MACD : | -1.5 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 13.3 |
D(3) : | 38 |
| RSI | RSI(14): 33.5 |
|||
| 52-week | High : | 72.29 | Low : | 30.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APGE ] has closed below the lower bollinger band by 4.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ APGE ] is to continue within current trading range. Bollinger Bands are 16.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.3 - 41.59 | 41.59 - 41.81 |
| Low: | 38.03 - 38.41 | 38.41 - 38.7 |
| Close: | 38.82 - 39.33 | 39.33 - 39.72 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Fri, 10 Jan 2025
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares - MarketBeat
Fri, 10 Jan 2025
CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus.com
Fri, 10 Jan 2025
Apogee Therapeutics (NASDAQ:APGE) Shares Down 9.1% - What's Next? - MarketBeat
Wed, 08 Jan 2025
Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Wed, 25 Dec 2024
This Apogee Therapeutics Insider Increased Their Holding In The Last Year - Yahoo Finance
Mon, 02 Dec 2024
Apogee Therapeutics Reports Breakthrough Half-Life Data for Key Drug Candidates APG777, APG808 - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 127.2 (%) |
| Shares Short | 7,970 (K) |
| Shares Short P.Month | 6,620 (K) |
| EPS | -2.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.6 % |
| Return on Equity (ttm) | -25.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -133 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -16.19 |
| PEG Ratio | 0 |
| Price to Book value | 3.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|